LEXINGTON, Mass. – MC10, maker of body-worn computing systems, has completed its two-and-a-half year collaboration with biopharmaceutical company UCB to study the application of wearable, ambulatory sensors to provide clinical-grade data on Parkinson’s disease.
“Our collaboration with UCB has allowed us to grow as a company by better understanding the needs of patients and the pharmaceutical industry’s efforts and approaches to meeting their needs,” said Scott Pomerantz, CEO of MC10, in a statement.
The study examined the feasibility of monitoring Parkinson’s disease patients in clinic and home settings while wearing sensors built with MC10’s epidermal electronics platform. In addition to data recorded from the wearable sensors, researchers also collected neurological assessments from trained clinicians and patient-reported outcomes.
“Completion of this study is testament to UCB’s mission to foster innovation to help the millions of people living with chronic neurodegenerative diseases,” said Erik Janssen, vice president Global New Patient Solutions, Neurology, at UCB. “UCB is focused on improving understanding about patient experiences, and evolving these insights to improve the management of neurological conditions—providing patients with better control and allowing them to improve treatment outcomes.”
The results of the study are being prepared by both companies for presentation and scientific publication later this year.
“We hope these results, once disseminated, will influence the broader community’s thinking about the place of novel technologies in patient care,” said Janssen.